Less Volume, More Premium: Post-Ozempic Economics Are Killing The Quantity Model - Pfizer (NYSE:PFE), Pep

As millions take GLP-1 drugs, packaged food giants face declining volumes while protein brands and specialty grocers win.

Raccontata dabenzinga.com